Hassanpour Kiana, Nourinia Ramin, Gerami Ebrahim, Mahmoudi Ghavam, Esfandiari Hamed
Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Ophthalmic Vis Res. 2021 Jul 29;16(3):415-431. doi: 10.18502/jovr.v16i3.9438. eCollection 2021 Jul-Sep.
Sturge-Weber syndrome (SWS) or encephalotrigeminal angiomatosis is a non-inherited congenital disorder characterized by neurologic, skin, and ocular abnormalities. A somatic activating mutation (R183Q) in the gene during early embryogenesis has been recently recognized as the etiology of vascular abnormalities in SWS. Approximately, half of the patients with SWS manifest ocular involvement including glaucoma as the most common ocular abnormality followed by choroidal hemangioma (CH). The underlying pathophysiology of glaucoma in SWS has not been completely understood yet. Early onset glaucoma comprising 60% of SWS glaucoma have lower success rates after medical and surgical treatments compared with primary congenital glaucoma. Primary angle surgery is associated with modest success in the early onset SWS glaucoma while the success rate significantly decreases in late onset glaucoma. Filtration surgery is associated with a higher risk of intraoperative and postoperative choroidal effusion and suprachoroidal hemorrhage. CH is reported in 40-50% of SWS patients. The goal of treatment in patients with CH is to induce involution of the hemangioma, with reduction of subretinal and intraretinal fluid and minimal damage to the neurosensory retina. The decision for treating diffuse CHs highly depends on the patient's visual acuity, the need for glaucoma surgery, the presence of subretinal fluid (SRF), its chronicity, and the potential for visual recovery.
斯特奇-韦伯综合征(SWS)或脑三叉神经血管瘤病是一种非遗传性先天性疾病,其特征为神经、皮肤和眼部异常。近期研究发现,早期胚胎发育过程中该基因的体细胞激活突变(R183Q)是SWS血管异常的病因。大约一半的SWS患者会出现眼部病变,其中青光眼是最常见的眼部异常,其次是脉络膜血管瘤(CH)。SWS相关性青光眼的潜在病理生理学机制尚未完全明确。与原发性先天性青光眼相比,早发性青光眼(占SWS相关性青光眼的60%)在药物和手术治疗后的成功率较低。原发性房角手术对早发性SWS青光眼有一定疗效,但对迟发性青光眼的成功率则显著降低。滤过性手术会增加术中及术后脉络膜渗漏和脉络膜上腔出血的风险。40%-50%的SWS患者会出现CH。CH患者的治疗目标是促使血管瘤消退,减少视网膜下和视网膜内积液,并尽量减少对神经感觉视网膜的损伤。对于弥漫性CH的治疗决策在很大程度上取决于患者的视力、青光眼手术的必要性、视网膜下液(SRF)的存在情况及其慢性程度,以及视力恢复的可能性。